The global Drug Preclinical CRO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drug Preclinical CRO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Preclinical CRO Services.
Report Scope
The Drug Preclinical CRO Services market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drug Preclinical CRO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug Preclinical CRO Services companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
LabCorp
IQVIA
PPD
滨颁翱狈锛圥搁础锛�
Charles River
WuXi AppTec
Pharmaron
Joinn Laboratories
Shanghai Medicilon
PharmaLegacy Laboratories
ChemPartner PharmaTech
Crown Bioscience
Segment by Type
Pharmacodynamic evaluation service
Pharmacokinetic Evaluation Service
Segment by Application
Biopharmaceutical Company
Scientific Research Unit
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Preclinical CRO Services companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Preclinical CRO Services 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pharmacodynamic evaluation service
1.2.3 Pharmacokinetic Evaluation Service
1.3 麻豆原创 by Application
1.3.1 Global Drug Preclinical CRO Services 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biopharmaceutical Company
1.3.3 Scientific Research Unit
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Preclinical CRO Services 麻豆原创 Perspective (2019-2030)
2.2 Drug Preclinical CRO Services Growth Trends by Region
2.2.1 Global Drug Preclinical CRO Services 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drug Preclinical CRO Services Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Drug Preclinical CRO Services Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Drug Preclinical CRO Services 麻豆原创 Dynamics
2.3.1 Drug Preclinical CRO Services Industry Trends
2.3.2 Drug Preclinical CRO Services 麻豆原创 Drivers
2.3.3 Drug Preclinical CRO Services 麻豆原创 Challenges
2.3.4 Drug Preclinical CRO Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug Preclinical CRO Services Players by Revenue
3.1.1 Global Top Drug Preclinical CRO Services Players by Revenue (2019-2024)
3.1.2 Global Drug Preclinical CRO Services Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Drug Preclinical CRO Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug Preclinical CRO Services Revenue
3.4 Global Drug Preclinical CRO Services 麻豆原创 Concentration Ratio
3.4.1 Global Drug Preclinical CRO Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Preclinical CRO Services Revenue in 2023
3.5 Drug Preclinical CRO Services Key Players Head office and Area Served
3.6 Key Players Drug Preclinical CRO Services Product Solution and Service
3.7 Date of Enter into Drug Preclinical CRO Services 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Preclinical CRO Services Breakdown Data by Type
4.1 Global Drug Preclinical CRO Services Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Drug Preclinical CRO Services Forecasted 麻豆原创 Size by Type (2025-2030)
5 Drug Preclinical CRO Services Breakdown Data by Application
5.1 Global Drug Preclinical CRO Services Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Drug Preclinical CRO Services Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Drug Preclinical CRO Services 麻豆原创 Size (2019-2030)
6.2 North America Drug Preclinical CRO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drug Preclinical CRO Services 麻豆原创 Size by Country (2019-2024)
6.4 North America Drug Preclinical CRO Services 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug Preclinical CRO Services 麻豆原创 Size (2019-2030)
7.2 Europe Drug Preclinical CRO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drug Preclinical CRO Services 麻豆原创 Size by Country (2019-2024)
7.4 Europe Drug Preclinical CRO Services 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug Preclinical CRO Services 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Drug Preclinical CRO Services 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drug Preclinical CRO Services 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Drug Preclinical CRO Services 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug Preclinical CRO Services 麻豆原创 Size (2019-2030)
9.2 Latin America Drug Preclinical CRO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drug Preclinical CRO Services 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Drug Preclinical CRO Services 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug Preclinical CRO Services 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Drug Preclinical CRO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drug Preclinical CRO Services 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Drug Preclinical CRO Services 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 LabCorp
11.1.1 LabCorp Company Detail
11.1.2 LabCorp Business Overview
11.1.3 LabCorp Drug Preclinical CRO Services Introduction
11.1.4 LabCorp Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.1.5 LabCorp Recent Development
11.2 IQVIA
11.2.1 IQVIA Company Detail
11.2.2 IQVIA Business Overview
11.2.3 IQVIA Drug Preclinical CRO Services Introduction
11.2.4 IQVIA Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.2.5 IQVIA Recent Development
11.3 PPD
11.3.1 PPD Company Detail
11.3.2 PPD Business Overview
11.3.3 PPD Drug Preclinical CRO Services Introduction
11.3.4 PPD Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.3.5 PPD Recent Development
11.4 滨颁翱狈锛圥搁础锛�
11.4.1 滨颁翱狈锛圥搁础锛� Company Detail
11.4.2 滨颁翱狈锛圥搁础锛� Business Overview
11.4.3 滨颁翱狈锛圥搁础锛� Drug Preclinical CRO Services Introduction
11.4.4 滨颁翱狈锛圥搁础锛� Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.4.5 滨颁翱狈锛圥搁础锛� Recent Development
11.5 Charles River
11.5.1 Charles River Company Detail
11.5.2 Charles River Business Overview
11.5.3 Charles River Drug Preclinical CRO Services Introduction
11.5.4 Charles River Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.5.5 Charles River Recent Development
11.6 WuXi AppTec
11.6.1 WuXi AppTec Company Detail
11.6.2 WuXi AppTec Business Overview
11.6.3 WuXi AppTec Drug Preclinical CRO Services Introduction
11.6.4 WuXi AppTec Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.6.5 WuXi AppTec Recent Development
11.7 Pharmaron
11.7.1 Pharmaron Company Detail
11.7.2 Pharmaron Business Overview
11.7.3 Pharmaron Drug Preclinical CRO Services Introduction
11.7.4 Pharmaron Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.7.5 Pharmaron Recent Development
11.8 Joinn Laboratories
11.8.1 Joinn Laboratories Company Detail
11.8.2 Joinn Laboratories Business Overview
11.8.3 Joinn Laboratories Drug Preclinical CRO Services Introduction
11.8.4 Joinn Laboratories Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.8.5 Joinn Laboratories Recent Development
11.9 Shanghai Medicilon
11.9.1 Shanghai Medicilon Company Detail
11.9.2 Shanghai Medicilon Business Overview
11.9.3 Shanghai Medicilon Drug Preclinical CRO Services Introduction
11.9.4 Shanghai Medicilon Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.9.5 Shanghai Medicilon Recent Development
11.10 PharmaLegacy Laboratories
11.10.1 PharmaLegacy Laboratories Company Detail
11.10.2 PharmaLegacy Laboratories Business Overview
11.10.3 PharmaLegacy Laboratories Drug Preclinical CRO Services Introduction
11.10.4 PharmaLegacy Laboratories Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.10.5 PharmaLegacy Laboratories Recent Development
11.11 ChemPartner PharmaTech
11.11.1 ChemPartner PharmaTech Company Detail
11.11.2 ChemPartner PharmaTech Business Overview
11.11.3 ChemPartner PharmaTech Drug Preclinical CRO Services Introduction
11.11.4 ChemPartner PharmaTech Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.11.5 ChemPartner PharmaTech Recent Development
11.12 Crown Bioscience
11.12.1 Crown Bioscience Company Detail
11.12.2 Crown Bioscience Business Overview
11.12.3 Crown Bioscience Drug Preclinical CRO Services Introduction
11.12.4 Crown Bioscience Revenue in Drug Preclinical CRO Services Business (2019-2024)
11.12.5 Crown Bioscience Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LabCorp
IQVIA
PPD
滨颁翱狈锛圥搁础锛�
Charles River
WuXi AppTec
Pharmaron
Joinn Laboratories
Shanghai Medicilon
PharmaLegacy Laboratories
ChemPartner PharmaTech
Crown Bioscience
听
听
*If Applicable.